Compare ZCMD & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZCMD | SBFM |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.0M |
| IPO Year | 2019 | N/A |
| Metric | ZCMD | SBFM |
|---|---|---|
| Price | $1.70 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 4.4M | 33.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $1.13 |
| 52 Week High | $1.87 | $3.90 |
| Indicator | ZCMD | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 83.56 | 42.38 |
| Support Level | $1.02 | $1.15 |
| Resistance Level | N/A | $1.52 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 86.83 | 25.00 |
ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.